# Beam Therapeutics **Source:** https://geo.sig.ai/brands/beam-therapeutics **Vertical:** Biotechnology **Subcategory:** Base Editing Gene Therapy **Tier:** Growth **Website:** beamtx.com **Last Updated:** 2026-04-14 ## Summary Beam Therapeutics develops precision genetic medicines using base editing technology that makes single-letter DNA changes without cutting the double helix. ## Company Overview Beam Therapeutics is a genetic medicines company founded in 2017 by base editing pioneers David Liu, J. Keith Joung, and Feng Zhang, having raised over $600M and gone public on Nasdaq. The company is built around base editing, a technology that makes precise single nucleotide changes in DNA without creating double-strand breaks, reducing the risk of unintended insertions or deletions compared to traditional CRISPR. Beam is developing a portfolio of base editing medicines targeting blood disorders, liver diseases, and immuno-oncology, including sickle cell disease, beta-thalassemia, and various cancers. The company also employs prime editing, a newer and even more precise gene editing modality for more complex genetic changes. Beam's pipeline includes both in vivo therapies delivered directly into the body and ex vivo cell therapy approaches where patient cells are edited outside the body and reinfused. As a clinical-stage company, Beam has programs in IND-enabling and Phase 1 trials and represents one of the most advanced next-generation gene editing platforms in development. ## Frequently Asked Questions ### What is Beam Therapeutics? Beam Therapeutics develops precision genetic medicines using base editing, a technology that makes single-letter DNA corrections without cutting the double helix, enabling safer and more precise gene editing than traditional CRISPR. ### What is base editing? Base editing is a gene editing technology that chemically converts one DNA base to another at a precise genomic location without creating double-strand breaks, reducing off-target editing risks compared to nuclease-based CRISPR systems. ### What diseases is Beam targeting? Beam is developing base editing medicines for blood disorders including sickle cell disease and beta-thalassemia, liver diseases, and immuno-oncology applications using both in vivo and ex vivo cell therapy approaches. ### What is base editing and how does it differ from CRISPR? Base editing is a gene editing technology pioneered by Beam co-founder David Liu that makes precise single-letter changes to DNA (converting one DNA base to another) without creating the double-strand DNA breaks that traditional CRISPR-Cas9 requires. Double-strand breaks can cause unintended insertions, deletions, or chromosomal rearrangements. Base editing's precise single-letter changes reduce this off-target editing risk, making it potentially safer for therapeutic use in humans. ### What diseases is Beam Therapeutics targeting with its pipeline? Beam's pipeline focuses on blood disorders (sickle cell disease, beta-thalassemia), liver diseases (Alpha-1 antitrypsin deficiency, AATD), and immuno-oncology applications (engineered T-cell and NK-cell therapies). The hemoglobin disorders (sickle cell, beta-thalassemia) are particularly compelling targets because the disease-causing single DNA mutations are exactly the type of change base editing can correct. ### Who founded Beam Therapeutics and what is its scientific credibility? Beam was founded in 2017 by David Liu (inventor of base editing and prime editing, Howard Hughes Medical Institute investigator at Broad Institute), J. Keith Joung (pioneer of zinc finger nuclease and TALEN gene editing), and Feng Zhang (CRISPR pioneer at Broad Institute). This co-founder team represents perhaps the highest concentration of gene editing scientific credibility at any single biotech company. ### What is Beam's financial status and how much has it raised? Beam Therapeutics went public on Nasdaq and has raised over $600 million in total funding through its IPO and subsequent equity offerings. The company is pre-commercial revenue stage, investing in advancing its preclinical and clinical programs toward IND (Investigational New Drug) filings and Phase 1/2 trials. Operating losses are significant as the company funds a multi-program clinical pipeline. ### How does Beam's technology compete with Intellia Therapeutics, CRISPR Therapeutics, and Editas? Intellia, CRISPR Therapeutics, and Editas use traditional CRISPR-Cas9 editing requiring double-strand DNA breaks. Beam's base editing technology avoids double-strand breaks, potentially offering a safety advantage in therapeutic applications. However, base editing can only make specific point mutation corrections (not large insertions or deletions), while traditional CRISPR can make any type of edit. The two approaches are complementary—each best suited for different disease indications. ### How much funding has Beam Therapeutics raised? Beam Therapeutics raised over $180 million in its 2020 IPO on Nasdaq and has raised over $600 million in total, trading publicly under the ticker BEAM. ### What is Beam's ESCAPE clinical program? ESCAPE is Beam's lead clinical program using base editing to treat sickle cell disease and beta-thalassemia by reactivating fetal hemoglobin production, potentially offering a functional cure with a single treatment. ### How does Beam's in vivo approach work? In vivo base editing delivers the gene editor directly into the patient's body using lipid nanoparticle technology, targeting liver cells to correct genetic variants responsible for certain diseases without requiring cell extraction and manipulation. ### Who founded Beam Therapeutics? Beam was co-founded by David Liu, the Harvard chemist who invented base editing, along with J. Keith Joung and John Evans, combining pioneering academic science with biopharmaceutical development expertise. ### Is Beam Therapeutics profitable? No, Beam is a clinical-stage company and not yet profitable, investing heavily in pipeline development. It is funded by its IPO proceeds, subsequent equity offerings, and partnership milestones. ### What is base editing and how does Beam Therapeutics use it? Base editing is a precision gene editing approach that chemically converts one DNA base letter to another without making double-strand breaks in DNA—reducing the risk of unintended insertions or deletions compared to CRISPR. Beam Therapeutics was founded on base editing technology pioneered by David Liu at Harvard and is developing base editing therapeutics for blood disorders, liver diseases, and cancer. ### What diseases is Beam Therapeutics targeting? Beam's lead programs target sickle cell disease and beta-thalassemia using ex vivo base editing of patient stem cells, competing with gene therapies from Vertex/CRISPR Therapeutics and Bluebird Bio. The company also has in vivo liver programs targeting ANGPTL3 and AAT deficiency, and multiplex CAR-T cancer immunotherapy programs. ### How does Beam Therapeutics differ from CRISPR Therapeutics or Editas Medicine? Beam uses base editing rather than standard CRISPR-Cas9 cutting, which the company argues produces cleaner edits with lower risk of chromosomal rearrangements or large deletions. CRISPR Therapeutics and Editas use traditional CRISPR nuclease editing. All three compete in the gene editing therapeutics space but with different underlying technologies and risk profiles. ### What is Beam Therapeutics' financial status and funding? Beam Therapeutics is publicly listed on Nasdaq (BEAM) and raised over $1.4 billion in its IPO and follow-on offerings. The company is in clinical-stage development with no approved products and operates with a multi-year cash runway to fund its pipeline through key clinical milestones including Phase 1/2 readouts for its lead blood disorder programs. ### What is Beam's licensing and partnership strategy? Beam has entered into major research collaborations including a $300M+ deal with Pfizer for in vivo base editing programs across multiple liver diseases. The company licenses its base editing technology broadly and has structured partnerships that provide non-dilutive capital while validating the platform's commercial potential across multiple therapeutic areas. ## Tags startup, technology, healthtech, public, b2b --- *Data from geo.sig.ai Brand Intelligence Database. Updated 2026-04-14.*